Despite the recent development in the field of second-generation FGFR-specific inhibitors, we and others observed several profound treatment responses in FGFR2-driven CCA with non-selective TKIs, even with reduced treatment doses compared to different tumor entities24,28,31. This evidence concerns the gene FGFR2 and neoplasm.